ABP-494

ABP-494 is an investigational **biosimilar cetuximab** candidate developed by Amgen in collaboration with Watson Pharmaceuticals. It is a **chimeric monoclonal antibody biologic** designed to match the reference anti-EGFR antibody cetuximab and to inhibit signaling through **epidermal growth factor receptor**, thereby suppressing tumor-cell proliferation and survival in EGFR-expressing cancers. Based on the provided context, the program was part of the Amgen-Watson oncology biosimilars collaboration and was intended for cancers for which cetuximab is used, particularly **colorectal cancer** and **head and neck cancer**.